

# Celiac Disease Therapeutic Pipeline Market Review, H2 2016

*Celiac Disease Treatment Pipeline Review H2 2016*

PUNE, INDIA, October 14, 2016 /EINPresswire.com/ -- This report provides comprehensive information on the therapeutic development for [Celiac Disease](#), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic



WISE GUY  
REPORTS

Norah Trent Partner Relations & Marketing Manager

✉ sales@wiseguyreports.com

☎ Ph: +1-646-845-9349 (US) Ph: +44 208 133 9349 (UK)

🌐 <https://www.linkedin.com/company/4828928>

🐦 <https://twitter.com/WiseGuyReports>

📘 <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Wise.Guy.

development for Celiac Disease and special features on late-stage and discontinued projects.

Get Sample Report @ <https://www.wiseguyreports.com/sample-request/275106-celiac-disease-pipeline-review-h2-2015>

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

## Scope

- The report provides a snapshot of the global therapeutic landscape of Celiac Disease
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Celiac Disease and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Celiac Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Celiac Disease pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

#### Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Celiac Disease
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Celiac Disease pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Buy 1-User PDF @ [https://www.wiseguyreports.com/checkout?currency=one\\_user-USD&report\\_id=275106](https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=275106)

#### Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Celiac Disease Overview 9

Therapeutics Development 10

Pipeline Products for Celiac Disease - Overview 10

Pipeline Products for Celiac Disease - Comparative Analysis 11

Celiac Disease - Therapeutics under Development by Companies 12

Celiac Disease - Therapeutics under Investigation by Universities/Institutes 13

Celiac Disease - Pipeline Products Glance 14

Clinical Stage Products 14

Early Stage Products 15

Unknown Stage Products 16

Celiac Disease - Products under Development by Companies 17

Celiac Disease - Products under Investigation by Universities/Institutes 18

Celiac Disease - Companies Involved in Therapeutics Development 19

Alba Therapeutics Corporation 19

Alvine Pharmaceuticals, Inc. 20

Amgen Inc. 21

Amyra Biotech AG 22

Avaxia Biologics, Inc. 23

Calypso Biotech SA 24

enGene, Inc 25

Glenmark Pharmaceuticals Ltd. 26

ImmusanT, Inc. 27

Intrexon Corporation 28  
Provid Pharmaceuticals, Inc. 29  
Selecta Biosciences, Inc. 30  
Sitari Pharmaceuticals, Inc. 31  
Zedira GmbH 32  
Celiac Disease - Therapeutics Assessment 33  
Assessment by Monotherapy Products 33  
...Continued

Access Report @ <https://www.wiseguyreports.com/reports/275106-celiac-disease-pipeline-review-h2-2015>

Follow Us:

LinkedIn: [www.linkedin.com/company/4828928](http://www.linkedin.com/company/4828928)

Twitter: <https://twitter.com/WiseGuyReports>

Facebook: <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Norah Trent

wiseguyreports

+1 646 845 9349 / +44 208 133 9349

email us here

---

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2016 IPD Group, Inc. All Right Reserved.